Project Title: Communicating about COVID-19 Testing to Underrepresented Populations.
Collaborators: Center of Excellence in Regulatory Science and Innovation (CERSI) and The Food and Drug Administration (FDA)

The goal of this project is to collect accurate and meaningful communications about COVID-19 testing in general and specifically from underrepresented populations, and to help the FDA better understand ways to protect the health of the public.

To do this, we want to understand what underrepresented populations think about COVID-19 testing and if they want to share their data in national information banks. What we learn from this study will help the FDA Center for Devices and Radiological Health (CDRH) tailor its health messages and inform its efforts for monitoring COVID-19 spread.
Communicating about COVID-19 Testing to Underrepresented Populations (continued)

The University of Maryland School of Pharmacy PATIENTS Program and University of Maryland at College Park collaborators will do a qualitative study using virtual focus group discussions and key informant interviews to get information from underrepresented people taking part in the greater Baltimore area. We will have three to five people from each underrepresented group with about 10-12 members per population of interest, implying a total of 3-6 key informant interviews or focus groups per population.

Underrepresented population groups of interest are:
1. African Americans of all ages
2. Individuals whose first language is Spanish of all ages
3. Older adults regardless of race or ethnicity
4. People who have trouble reading or can get, process and understand basic health information and services needed to make appropriate health decisions
5. People with chronic conditions
6. People with no symptoms of COVID-19 who live with people who have COVID-19